Protease Inhibitors to Reduce Malaria Morbidity in HIV-Infected Women.

Trial Profile

Protease Inhibitors to Reduce Malaria Morbidity in HIV-Infected Women.

Completed
Phase of Trial: Phase III

Latest Information Update: 04 Nov 2016

At a glance

  • Drugs Lopinavir/ritonavir (Primary) ; Efavirenz; Lamivudine; Zidovudine
  • Indications HIV infections; Malaria
  • Focus Therapeutic Use
  • Acronyms PROMOTE-PIs; PROMOTE-Pregnant Women and Infants
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 04 Nov 2016 Results published in the JAIDS
    • 01 Jul 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top